Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lorlatinib”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05740943
What this trial is testing

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Who this might be right for
Stage III NSCLCSurgery
Guangdong Provincial People's Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Not applicableApproved For MarketingNCT03127618
What this trial is testing

Lorlatinib - PF-06463922

Pfizer
Testing effectiveness (Phase 2)Active Not RecruitingNCT05297890
What this trial is testing

Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals 70
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableEnrolling By InvitationNCT06876675
What this trial is testing

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerHyperlipidemia
Peking University Third Hospital 167
Early research (Phase 1)Study completedNCT04541407
What this trial is testing

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Who this might be right for
Non Small Cell Lung CancerCNS Progression
University of Colorado, Denver 1
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Early research (Phase 1)Study completedNCT02564562
What this trial is testing

Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Who this might be right for
Healthy
Pfizer 6
Testing effectiveness (Phase 2)Looking for participantsNCT06007937
What this trial is testing

Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastaticRecurrent
Memorial Sloan Kettering Cancer Center 56
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Not applicableEnded earlyNCT04753658
What this trial is testing

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Who this might be right for
Neuroblastoma
Pfizer 15
Testing effectiveness (Phase 2)UnknownNCT03612154
What this trial is testing

Study of Lorlatinib in ROS1 Rearranged NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
National Cancer Center, Korea 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07083687
What this trial is testing

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer (NSCLC)
Hunan Cancer Hospital 21
Testing effectiveness (Phase 2)UnknownNCT03439215
What this trial is testing

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 20
Very early researchLooking for participantsNCT06333899
What this trial is testing

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Who this might be right for
High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more
Nationwide Children's Hospital 15
Testing effectiveness (Phase 2)Ended earlyNCT02584634
What this trial is testing

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 43
Load More Results